Hologic, Inc. $HOLX Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,828,325 shares of the medical equipment provider’s stock after acquiring an additional 97,142 shares during the period. Geode Capital Management LLC owned 2.62% of Hologic worth $378,209,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Chung Wu Investment Group LLC acquired a new stake in shares of Hologic in the second quarter worth $26,000. Caitong International Asset Management Co. Ltd increased its holdings in Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 273 shares in the last quarter. Zions Bancorporation National Association UT purchased a new position in Hologic in the first quarter valued at about $34,000. Cromwell Holdings LLC lifted its stake in shares of Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 436 shares in the last quarter. Finally, Allworth Financial LP boosted its position in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after buying an additional 216 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Performance

Hologic stock opened at $74.15 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $80.31. The company has a fifty day moving average price of $69.76 and a two-hundred day moving average price of $65.73. The company has a market cap of $16.49 billion, a PE ratio of 30.77, a P/E/G ratio of 2.54 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.03 billion. During the same period in the prior year, the company earned $1.01 earnings per share. The firm’s revenue was up 6.2% compared to the same quarter last year. Research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several recent research reports. Raymond James Financial downgraded shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $78.00 price target on shares of Hologic in a report on Wednesday, October 22nd. Leerink Partners lifted their price target on shares of Hologic from $70.00 to $78.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 21st. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and upped their price objective for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Finally, Mizuho lowered Hologic from an “outperform” rating to a “neutral” rating and lifted their target price for the stock from $70.00 to $78.00 in a research report on Thursday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $79.77.

Insider Buying and Selling

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the business’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christiana Stamoulis sold 7,402 shares of the company’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the transaction, the director owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.